全文获取类型
收费全文 | 28735篇 |
免费 | 1809篇 |
国内免费 | 345篇 |
专业分类
耳鼻咽喉 | 563篇 |
儿科学 | 407篇 |
妇产科学 | 458篇 |
基础医学 | 4583篇 |
口腔科学 | 424篇 |
临床医学 | 2231篇 |
内科学 | 5667篇 |
皮肤病学 | 1188篇 |
神经病学 | 2309篇 |
特种医学 | 1845篇 |
外科学 | 3718篇 |
综合类 | 144篇 |
现状与发展 | 1篇 |
一般理论 | 13篇 |
预防医学 | 1277篇 |
眼科学 | 857篇 |
药学 | 2435篇 |
中国医学 | 315篇 |
肿瘤学 | 2454篇 |
出版年
2023年 | 193篇 |
2022年 | 592篇 |
2021年 | 927篇 |
2020年 | 528篇 |
2019年 | 789篇 |
2018年 | 903篇 |
2017年 | 701篇 |
2016年 | 1042篇 |
2015年 | 1428篇 |
2014年 | 1677篇 |
2013年 | 1787篇 |
2012年 | 2669篇 |
2011年 | 2515篇 |
2010年 | 1637篇 |
2009年 | 1304篇 |
2008年 | 1636篇 |
2007年 | 1599篇 |
2006年 | 1407篇 |
2005年 | 1331篇 |
2004年 | 1075篇 |
2003年 | 900篇 |
2002年 | 868篇 |
2001年 | 390篇 |
2000年 | 375篇 |
1999年 | 314篇 |
1998年 | 166篇 |
1997年 | 130篇 |
1996年 | 112篇 |
1995年 | 104篇 |
1994年 | 71篇 |
1993年 | 66篇 |
1992年 | 163篇 |
1991年 | 162篇 |
1990年 | 128篇 |
1989年 | 160篇 |
1988年 | 124篇 |
1987年 | 122篇 |
1986年 | 103篇 |
1985年 | 86篇 |
1984年 | 80篇 |
1983年 | 53篇 |
1982年 | 38篇 |
1981年 | 43篇 |
1980年 | 38篇 |
1979年 | 37篇 |
1978年 | 31篇 |
1977年 | 27篇 |
1974年 | 30篇 |
1973年 | 29篇 |
1972年 | 27篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
21.
22.
Clinical pharmacokinetics of midazolam in intensive care patients, a wide interpatient variability? 总被引:7,自引:0,他引:7
H Oldenhof M de Jong A Steenhoek R Janknegt 《Clinical pharmacology and therapeutics》1988,43(3):263-269
The pharmacokinetics of midazolam and its metabolites were studied in 17 patients on mechanical ventilation in a general intensive care unit who were receiving a continuous intravenous infusion of midazolam, adjusted according to the level of induced sedation. Three patients were studied twice. Serum midazolam and alpha-hydroxymidazolamglucuronide levels were determined during and after infusion. The sedation level was scored on a four-point scale. Half of the observed patients were still drowsy or asleep 10 hours after termination of midazolam infusion. In only one patient was midazolam serum elimination half-life less than 2 hours and in six patients the half-life was greater than 10 hours. A wide range of midazolam serum levels was associated with adequate sedation, and similarly the midazolam levels at the moment of awakening were highly variable. The serum concentration ratio of midazolam/alpha-hydroxymidazolamglucuronide at the end of the infusion varied from 0.03 to 15.6. Renal function could account for only a part of this variation. 相似文献
23.
Jung Han Kim Sang Jun Lee Young Bok Han Jung Jo Moon Jong Bae Kim 《Archives of pharmacal research》1994,17(2):115-118
This paper describes the isolation of isoguanosine from Croton tiglium L. and its cytotoxic effect against several tumor cell lines in culture and newly reports that isoguanosine has an antitumor activity against implanted S-180 ascitic tumor mice. Isoguanosine is effective at the dose of 24 mg/kg/day x 5, with T/C value of 168%. Isoguanosine inhibits the growth of S-180 and Ehrlich solid tumor in mice at the optimal doses of 96 mg/kg/day x 12 and 48 mg/kg/day x 12, with 1-T/C values of 65% and 60%, respectively. 相似文献
24.
25.
Navis G. J.; Dullaart R. P. F.; Vellenga E.; Elema J. D.; de Jong P. E 《Nephrology, dialysis, transplantation》1994,9(10):1477-1481
POEMS syndrome is a multisystem disorder associated with plasmacell dyscrasias. This report describes a patient with POEMS-associatedrenal disease and reviews the literature on biopsy-proven renalinvolvement in POEMS syndrome. Our patient had glomerulonephritiswith membranoproliferative features on light-microscopy withoutcharacteristic findings on immunofluorescence, and with ultra-structural evidence of glomerular microangiopathy. Ultrastructuralevidence of microangiopathy was also found in vasa nervorum.In 20 other cases of POEMS- associated renal disease, 16 hadglomerular disease. Light-microscopy showed membranoproliferative-likeglomerulopathy in 14 patients and glomerular microan giopathyin two. Ultrastructural evidence of microangi opathy was presentin all 15 patients in whom electron- microscopy was done. Thus,in most patients with POEMS-associated glomerular disease acharacteristic lesion is present with evidence of endothelialinjury. As endothelial damage is also found in endoneural vessels,generalized endothelial injury may play a role in non-renalmanifestations of POEMS syndrome. In previous reviews manifestationsof the POEMS syndrome were similar for patients with or withoutmyeloma. Among patients with biopsy-proven glomerular disease,however, myeloma patients are underrepres ented. Whether thisrepresents a sampling error or has true pathophysiological significanceremains to be established. 相似文献
26.
Kyung Bok Lee Jong Sig Kim Sang Tae Kwak Wonbo Sim Jong Hwan Kwak Yeong Shik Kim 《Archives of pharmacal research》1998,21(5):555-558
Chondroitin sulfates were isolated from the mud snail. For the quantitative analysis of enzymatic digestion products of isolated
chondroitin sulfates, strong anion exchange-high performance liquid chromatography (SAX-HPLC) was performed. By the action
of chondroitinase ABC, three unsaturated disaccharides 2-acetamide-2-deoxy-3-O-(β-D-gluco-4-enepyranosyluronic acid)-D-galactose (ΔDi-OS), 2-acetamide-2-deoxy-3-O-(β-D-gluco-4-enepyranosyluronic acid)-6-O-sulfo-D-galactose (ΔDi-6S) and 2-acetamide-2-deoxy-3-O-(β-D-gluco-4-enepyranosyluronic acid)-4-O-sulfo-D-galactose (ΔDi-4S) were produced from the mud snail chondroitin sulfates. The analysis showed that relative proportion
of ΔDi-OS/ΔDi-6S/ΔDi-4S was 58.7/3.1/38.2. The immunomodulating activity of chondroitin sulfate was examined by cell proliferation
assay and these results suggest that it might be a immunosuppressant. 相似文献
27.
28.
29.
Su Jin Park Su Jin Kim Yumie Rhee Ji Hyun Byun Seong Hwan Kim Myoung Hee Kim Eun Jig Lee Sung-Kil Lim 《Journal of bone and mineral research》2007,22(6):889-896
The FIGNL1 gene was proven to be a new subfamily member of ATPases associated with diverse cellular activities (AAA proteins). In this in vitro study, the AAA proteins inhibited osteoblast proliferation and stimulated osteoblast differentiation. We showed that FIGNL1 may play some regulatory role in osteoblastogenesis. INTRODUCTION: The fidgetin-like 1 (FIGNL1) gene encodes a new subfamily member of ATPases associated with diverse cellular activities (AAA proteins). Although the FIGNL1 protein localizes to both the nucleus and cytoplasm, the function of FIGNL1 remains unknown. In a previous study, we identified several genes that mediate the anabolic effects of basic fibroblast growth factor (bFGF) on bone by using microarray data. FIGNL1 was one of the genes that downregulated >2-fold in MC3T3-E1 cells after treatment with bFGF. Therefore, this study was aimed to identify and confirm the function of FIGNL1 on osteoblastogenesis. MATERIALS AND METHODS: We examined the effect of the FIGNL1 gene on proliferation, differentiation, and apoptosis in mouse osteoblast cells (MC3T3-E1 and mouse primary calvarial cells) using flow cytometry, RT-PCR, cell proliferation assay, and cell death assay. MC3T3-E1 cells and mouse calvarial cells were transfected with small interfering RNA (siRNA) directed against the FIGNL1 or nontargeting control siRNA and examined by cell proliferation and cell death assays. Also, FIGNL1 was fused to enhance green fluorescent protein (EGFP), and the EGFP-fused protein was transiently expressed in MC3T3-E1 cells. RESULTS: Reduced expression of FIGNL1 by bFGF and TGF-beta1 treatment was verified by RT-PCR analysis. Overexpression of FIGNL1 reduced the proliferation of MC3T3-E1 and calvarial cells, more than the mock transfected control cells did. In contrast, siFIGNL1 transfection significantly increased the proliferation of osteoblasts, whereas overexpression of FIGNL1 did not seem to alter apoptosis in osteoblasts. Meanwhile, overexpression of FIGNL1 enhanced the mRNA expression of alkaline phosphatase (ALP) and osteocalcin (OCN) in osteoblasts. In contrast, siFIGNL1 decreased the expression of ALP and OCN. A pEGFP-FIGNL1 transfected into MCT3-E1 cells had an initially ubiquitous distribution and rapidly translocated to the nucleus 1 h after bFGF treatment. CONCLUSIONS: From these results, we proposed that FIGNL1, a subfamily member of the AAA family of proteins, might play some regulatory role in osteoblast proliferation and differentiation. Further analyses of FIGNL1 will be needed to better delineate the mechanisms contributing to the inhibition of proliferation and stimulation of osteoblast differentiation. 相似文献
30.
Jong Il Kim Takeshi Tsujino Yoshio Fujioka Komei Saito Mitsuhiro Yokoyama 《Hypertension research》2003,26(4):307-313
We examined cellular membrane fatty acid composition and insulin sensitivity in patients with mild essential hypertension and hyperlipidemia, and investigated whether bezafibrate, a lipid-lowering drug, could improve elevated blood pressure and insulin sensitivity in these subjects by ameliorating cellular membrane fatty acid composition. Twenty-seven subjects were recruited. Twelve men with mild essential hypertension [systolic blood pressure (SBP) between 140 mmHg and 160 mmHg] and hypertriglyceridemia (plasma triglyceride concentration over 150 mg/dl) were designated the HL group. Fifteen men with mild essential hypertension and normotriglyceridemia (plasma triglyceride concentration below 150 mg/dl) were designated the NL group. Subjects in the HL group were given bezafibrate 400 mg/dl and those in the NL group were given placebo for 3 months. Bezafibrate significantly reduced SBP (140 +/- 2.6 to 131.8 +/- 2.6 mmHg, mean +/- SEM), diastolic blood pressure (DBP) (87.8 +/- 2.0 to 82.8 +/- 2.6 mmHg), fasting plasma triglyceride concentration (225.5 +/- 23.5 to 102.9 +/- 10.9 mg/dl), fasting plasma insulin concentration (9.6 +/- 0.8 to 7.1 +/- 0.8 microU/ml), and homeostasis model assessment scores (HOMA-R, 2.4 +/- 0.2 to 1.7 +/- 0.2), and significantly improved the insulin sensitivity index (56.0 +/- 3.0 to 70.7 +/- 4.8 mg x l2/mmol x mU x min) in the HL group. Regarding erythrocyte membrane fatty acid composition, bezafibrate reduced the percentages of saturated fatty acids (SFA) and increased the percentage of polyunsaturated fatty acids (PUFA). Plasma triglyceride concentrations were positively correlated with HOMA-R (r = 0.50, p < 0.01) and SFA (r = 0.39, p < 0.05), and negatively correlated with PUFA (r = -0.45, p < 0.05) before administration of placebo or bezafibrate. In conclusion, an improvement of hyperlipidemia by bezafibrate may be attributed to reduction of blood pressure and amelioration of insulin sensitivity. Abnormalities in membrane lipid composition may play an important role in these metabolic disorders. 相似文献